Biobanks in oncology: global experience and Russian reality

Cover Page

Abstract


One of the integral components of modern large-scale research projects in the field of medicine are biobanks. The main objective of this infrastructure is the professional collection of biological samples that can be studied with respect to a wide range of molecular biological parameters and will not lose their information value over a long storage period. These samples are made informative not only by correctly conducted preanalytical preparation at the stage of taking samples and placing them in storage, but also by detailed information support (the so-called annotated samples). The sample annotation is the fully collected personal, clinical and laboratory data about a patient. An important point of the biobank infrastructure is compliance with regulatory legal acts and ethical standards, including the procedure for signing an informed consent by a patient about voluntary donation of biological samples and the use of personal data. All this ensures the implementation of the main objective of creating biobanks – the wide and uninterrupted availability of collections of biological material for researchers and developers and compliance with specific scientific tasks. This review is devoted to biobanking issues, as well as to the description and analysis of the currently existing oncological biobank infrastructure, both globally and within the Russian Federation.


Full Text

Restricted Access

About the authors

Andrei D. Kaprin

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Author for correspondence.
Email: grivtsova@mail.ru
ORCID iD: 0000-0001-8784-8415

Russian Federation, Obninsk

D. Sci. (Med.), Prof., Acad. RAS

Sergei A. Ivanov

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Email: grivtsova@mail.ru
ORCID iD: 0000-0001-7689-6032

Russian Federation, Obninsk

D. Sci. (Med.), Prof.

Vladimir A. Petrov

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Email: grivtsova@mail.ru
ORCID iD: 0000-0002-8580-933X

Russian Federation, Obninsk

D. Sci. (Med.)

Natalia N. Dukhova

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Email: grivtsova@mail.ru
ORCID iD: 0000-0002-7186-8531

Russian Federation, Obninsk

Res. Officer

Nina Iu. Dvinskikh

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Email: grivtsova@mail.ru

Russian Federation, Obninsk

Cand. Sci. (Med.)

Natalia A. Falaleeva

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Email: grivtsova@mail.ru

Russian Federation, Obninsk

D. Sci. (Med.)

Liudmila Iu. Grivtsova

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre

Email: grivtsova@mail.ru
ORCID iD: 0000-0001-9103-9688

Russian Federation, Obninsk

D. Sci. (Biol.)

References

  1. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019. [Malignant neoplasms in Russia in 2018 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinskij, G.V. Petrova. Moscow, 2019 (in Russian).]
  2. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10 (3): 139–52. doi: 10.1097/00019606-200109000-00001
  3. Bazel R. Her-2: the making of Herceptin, a revolutionary treatment for breast cancer. Random House, 1998.
  4. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101 (36): 13306–11. doi: 10.1073/pnas.0405220101
  5. Каприн А.Д., Галкин В.Н., Жаворонков Л.П. и др. Синтез фундаментальных и прикладных исследований – основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017; 26 (2): 26–37. [Kaprin A.D., Galkin V.N., Zhavoronkov L.P. et al. Sintez fundamental’nyh i prikladnyh issledovanij – osnova obespecheniya vysokogo urovnya nauchnyh rezul’tatov i vnedreniya ih v medicinskuyu praktiku. Radiaciya i risk. 2017; 26 (2): 26–37 (in Russian).]
  6. Riegman PH, Morente MM, Betsou F et al. Biobanking for better healthcare. Mol Oncol 2008; 2 (3): 213–22. doi: 10.1016/j.molonc.2008.07.004
  7. Смирнова Ю. Банковское дело, как путь к персонифицированной медицине. Наука и жизнь. 2013; 1: 14. [Smirnova Iu. Bankovskoe delo, kak put’ k personifitsirovannoi meditsine. Nauka i zhizn’. 2013; 1: 14 (in Russian).]
  8. Fransson MN, Rial-Sebbag E, Brochhausen M et al. Toward a common language forbiobanking. Eur J Hum Genet 2015; 23 (1): 22–8. doi: 10.1038/ejhg.2014.45
  9. Dawber TR, Kannel WB. The Framingham Study. An epidemiologic approach to coronary heart disease. Circulation 1966; 34 (4): 553–55. doi: 10.1161/01.cir.34.4.553
  10. Asslaber M, Zatloukal K. Biobanks: transnational, European and global networks. Brief Funct Genom Proteomics 2007;6 (3): 193–201. doi: 10.1093/bfgp/elm023.
  11. Swede H, Stone CL, Norwood AR. National population-based biobanks for genetic research. Genet Med 2007; 9 (3): 141–9. doi: 10.1097/gim.0b013e3180330039
  12. Mohamadkhani A, Poustchi H. Repository of Human Blood Derivative Biospecimens in Biobank: Technical Implications. Middle East J Dig Dis 2015; 7 (2): 61–8.
  13. Andersson K, Bray F, Arbyn M et al. The interface of population-based cancer registries and biobanks in etiological and clinical research–current and future perspectives. Acta Oncol 2010; 49 (8): 1227–34. doi: 10.3109/0284186X.2010.496792
  14. Elliott P, Peakman TC. The UK Biobank sample handlingand storage protocol for the collection, processing and archivingof human blood and urine. Int J Epidemiol 2008; 37 (2): 234–44. doi: 10.1093/ije/dym276
  15. Paskal W, Paskal АM, Dębski Т et al. Aspects of Modern Biobank Activity – Comprehensive Review. Pathol Oncol Res 2018; 24: 771–85.
  16. Kofanova OA, Mommaerts K, Betsou F. Tube Polypropylene: A Neglected Critical Parameter for Protein Adsorption During Biospecimen Storage. Biopreserv Biobank 2015; 13 (4): 296–8. doi: 10.1089/bio.2014.0082
  17. ISO 20387:2018. https://www.iso.org/standard/67888.html
  18. Guerin JS, Murray DW, McGrath MM et al. Molecular medicine ireland guidelines for standardized biobanking. Biopreserv Biobank 2010; 8 (1): 3–63. doi: 10.1089/bio.2010.8101
  19. Leitsalu L, Haller T, Esko T et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol 2015; 44 (4): 1137–47. doi: 10.1093/ije/dyt268
  20. Zawati M, Borry P, Howard H et al. Closure of populationbiobanks and direct-to-consumer genetic testing companies. Hum Genet 2011; 130 (3): 425–32. doi: 10.1007/s00439-011-1019-4
  21. Awadalla P, Boileau C, Payette Y et al. Cohort profile of the CARTaGENE study: Quebec’s population-based biobank for public health and personalized genomics. Int J Epidemiol 2013; 42 (5): 1285–99. doi: 10.1093/ije/dys160
  22. Bonnelykke K, Sleiman P, Nielsen K et al. Agenome-wideas sociation study identifies CDHR3 asasus ceptibility locus for early childhoodasthm a with sever exacerbations. Nat Genet 2014; 46 (1): 51–5.
  23. Haukkala A, Kujala E, Alha P et al. The return of unexpected research results in a biobankstudy and referral to health care for heritable long QT syndrome. Public Health Genomics 2013; 16 (5): 241–50. doi: 10.1159/000354105
  24. Wood AR, Esko T, Yang J et al. Defining the role of common variation in the genomicand biological architecture of adult human height. Nat Genet 2014; 46 (11): 1173–86. doi: 10.1038/ng.3097
  25. Reza M, Cox D, Phillips L et al. MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide. Neuromuscul Disord 2017; 27 (11): 1054–64. doi: 10.1016/j.nmd.2017.07.001
  26. De Souza YG, Greenspan JS Biobanking past, present and future: responsibilitie sand benefits. AIDS (London) 2013; 27 (3): 303–12. doi: 10.1097/QAD.0b013e32835c1244
  27. Check Hayden E. Proposed Ebola biobank would strengthen African science. Nature 2015; 524 (7564): 146–7. doi: 10.1038/524146a
  28. Riegman PH, Morente MM, Betsou F et al. Biobanking for better healthcare. Mol Oncol 2008; 2 (3): 213–22. doi: 10.1016/j.molonc.2008.07.004
  29. Goebell PJ, Morente MM. New concepts of biobanks – strategic chance for uro-oncology. Urol Oncol 2010; 28 (4): 449–57. doi: 10.1016/j.molonc.2008.07.004
  30. Ose J, Fortner RT, Schock H et al. Bueno-de-Mesquita HBetal Insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 2015; 112 (1): 162–6. doi: 10.1038/bjc.2014.566
  31. McKenzie F, Ferrari P, Freisling H et al. Healthy life style and risk of breast cancer among postmenopausal women in the European Prospective Investigation into Cancerand Nutrition cohort study. Int J Cancer 2015; 136 (11): 2640–8. doi: 10.1002/ijc.29315
  32. Engeset D, Braaten T, Teucher B et al. Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort. Eur J Epidemiol 2015; 30 (1): 57–70. doi: 10.1007/s10654-014-9966-4
  33. Shui IM, Lindstrom S, Kibel AS et al. Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol 2014; 65 (6): 1069–75. DOI: 10.1016
  34. Schumacher FR, Olama AA, Berndt SI et al. Association analyses of more than 140,000 men identify 63 new prostate сancer susceptibility loci. Nat Genet 2018; 50 (7): 928–36. doi: 10.1038/s41588-018-0142-8
  35. Erbas В, Provenzano Е, Armes J et al. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 2006; 97 (2): 135–44. doi: 10.1007/s10549-005-9101-z
  36. Peila R, Arthur R, Rohan TE. Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study. Cancer Epidemiol 2020; 64 (101648). doi.org/10.1016/j.canep.2019.101648
  37. Knuiman MW, Jamrozik K, Welborn TA et al. Age and secular trends in risk factors for cardiovascular disease in Busselton. Australian J Public Health 1995; 19 (4): 375–82. doi: 10.1111/j.1753-6405.1995.tb00389.x
  38. Knuiman MW, Hung J, Divitini ML et al. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prevention Rehabilitation 2009; 16 (2): 235–41. doi.org/10.1097/HJR.0b013e32832955fc
  39. Li M, Eastman CJ, Waite KV et al. Are Australian children iodine deficient? Results of the Australian National Iodine Nutrition Study. Med J Australia 2006; 184 (4): 165–9.
  40. Chan YX, Matthew W. Knuiman et al. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur J Endocrinol 2017; 177: 297–308.
  41. Liao X, Lochhead P, Nishihara R et al. Aspirin Use, Тumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med 2012; 367 (17): 1596–606. doi: 10.1056/NEJMoa1207756
  42. Betancourt LH, Szasz AM, Kuras M et al. The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes. Cancers (Basel) 2019; 11 (12): 2–18. doi: 10.3390/cancers11121981
  43. Lee YM, Grauffel C, Chen T et al. Factors Governing the Different Functions of Zn2+-Sites with Identical Ligands in Proteins. J Chem Inf Model 2019; 59 (9): 3946–54. doi: 10.1021/acs.jcim.9b00617
  44. Haslacher H, Bayer M, Fiegl H et al. Quality management at the national biobanking level – establishing a culture of mutual trust and support: the BBMRI. at example. Clin Chem Lab Med 2019; 57 (12): 301–5. doi: 10.1515/cclm-2019-0491
  45. Kozlakidis Z. Strides forward in biobanking ethics. Lancet Public Health 2019; 4 (10): 495. doi: 10.1016/S2468-2667(19)30154-9
  46. Jang AY, Kim S, Park SJ et al. A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort. Clin Hypertens 2019; 25 (21). doi: 10.1186/s40885-019-0126-8
  47. Shin KH, Kim HH, Kwon BS et al. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Ann Lab Med 2020; 40 (1): 40–7. doi: 10.3343/alm.2020.40.1.40
  48. Chernobyl Tissue Bank. https://www.chernobyltissuebank.com/
  49. Иванов С.А., Петров В.А., Гривцова Л.Ю. и др. Международный опыт создания и развития биобанков. Что мы возьмем в работу? Материалы итоговой научно-практической конференции «Радиация и организм». Обнинск, 2019; c. 62–5. [Ivanov S.A., Petrov V.A., Grivtsova L.Iu. et al. Mezhdunarodnyi opyt sozdaniia i razvitiia biobankov. Chto my voz’mem v rabotu? Materialy itogovoi nauchno-prakticheskoi konferentsii «Radiatsiia i organizm’. Obninsk, 2019; p. 62–5 (in Russian).]
  50. Гривцова Л.Ю., Духова Н.Н., Семенова Н.С. и др. Первые шаги по созданию отечественного сетевого онкобиобанка. Материалы итоговой научно-практической конференции «Радиация и организм». Обнинск, 2019; c. 41–3. [Grivtsova L.Iu., Dukhova N.N., Semenova N.S. et al. Pervye shagi po sozdaniiu otechestvennogo setevogo onkobiobanka. Materialy itogovoi nauchno-prakticheskoi konferentsii «Radiatsiia i organizm’. Obninsk, 2019; p. 41–3 (in Russian).]
  51. Семененко Т.А. Роль банка сывороток крови в системе биологической безопасности страны. Вестн. Росздравнадзора. 2010; 3: 55–8. [Semenenko T.A. Rol’ banka syvorotok krovi v sisteme biologicheskoi bezopasnosti strany. Vestn. Roszdravnadzora. 2010; 3: 55–8 (in Russian).]

Statistics

Views

Abstract - 34

PDF (Russian) - 0

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies